JAN 1 3 2003 2

80-11-1

GP1635

PATENA 09/760;574 454313-3154.1

MANUAL UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

AUDONNET et al.

Serial No.

09/760,574

Filing Date

January 16, 2001

For

IMPROVED DNA VACCINES FOR FARM ANIMALS, IN

PARTICULAR BOVINES AND PORCINES

Examiner

Jon E. Angell

Art Unit

1635

745 Fifth Avenue, New York, NY 10151

EXPRESS MAIL

Mailing Label Number:

EV 141991974 US

Date of Deposit:

January 13, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to: Commissioner for Patents, Washington, DC 20231.

(Typed or printed name of person mailing paper or fee)

(Signature of person mailing paper or fee)

RECEIVED

JAN 1 6 2003

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO OFFICE ACTION WITH REQUESTS FOR EXTENSION OF TIME AND INTERVIEW

Assistant Commissioner for Patents

Washington, D.C. 20231

Dear Sir:

This is in response to the September 12, 2002 Office Action, which set a three month period for reply.

REQUEST FOR EXTENSION OF TIME

It is respectfully requested that the period for reply be extended one month, i.e., to up to and including January 13, 2003, as January 12 is a Sunday. Submitted herewith is a check for \$110.00 in payment of the fee therefor. The Commissioner is authorized to charge any additional fee for the extension, or any fee occasioned by this paper, or credit any overpayment in such fees, to Deposit Account No. 50-0320.

01/15/2003 SZEUDIE1 00000015 09760574

01 FC:1251

110.00 OP

-1-

00106631

AMENDMENT

Please amend the application without prejudice, without admission, without surrender of subject matter and without intention of creating any estoppel as to equivalents, as follows:

IN THE CLAIMS

Please add the following claims without prejudice, without admission, without surrender of subject matter and without intention of creating any estoppel as to equivalents:

Plasmid that contains and expresses in a bovine host cell a nucleotide sequence encoding an immunogen of the bovine pathogen, and a cationic lipid containing a quaternary ammonium salt, of the formula

in which R_1 is a saturated or unsaturated linear aliphatic radical having 12 to 18 carbon atoms, R_2 is an aliphatic radical containing 2 or 3 carbon atoms, and X a hydroxyl or amine group.

- 85. (New) The vaccine according to claim 84, further comprising DOPE.
- 86. (New) The vaccine according to claim 84, further comprising bovine GM-CSF.
- 87. (New) The vaccine according to claim 85, further comprising bovine GM-CSF.
- 88. (New) The vaccine according to claim 84, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF.
- 89. (New) The vaccine according to claim 85, further comprising an expression vector that contains and expresses in a bovine host cell a nucleotide sequence encoding bovine GM-CSF.
- 90. (New) The vaccine according to claim 88, wherein the expression vector is a plasmid.
- 91. (New) The vaccine according to claim 89, wherein the expression vector is a plasmid.

A